EAGLE PHARMACEUTICALS INC (EGRX)
US2697961082 - Common Stock
EGRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. EGRX has an excellent profitability rating, but there are some minor concerns on its financial health. EGRX has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year EGRX was profitable.
EGRX had a negative operating cash flow in the past year.
Of the past 5 years EGRX 4 years were profitable.
In the past 5 years EGRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.99%, EGRX belongs to the top of the industry, outperforming 95.22% of the companies in the same industry.
EGRX has a Return On Equity of 4.80%. This is amongst the best in the industry. EGRX outperforms 95.56% of its industry peers.
EGRX has a Return On Invested Capital of 10.53%. This is amongst the best in the industry. EGRX outperforms 96.76% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EGRX is in line with the industry average of 13.86%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROIC | 10.53% |
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
1.3 Margins
Looking at the Profit Margin, with a value of 4.70%, EGRX belongs to the top of the industry, outperforming 95.22% of the companies in the same industry.
In the last couple of years the Profit Margin of EGRX has declined.
EGRX has a Operating Margin of 16.47%. This is amongst the best in the industry. EGRX outperforms 96.76% of its industry peers.
In the last couple of years the Operating Margin of EGRX has declined.
EGRX has a Gross Margin of 69.86%. This is amongst the best in the industry. EGRX outperforms 84.30% of its industry peers.
In the last couple of years the Gross Margin of EGRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% |
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EGRX is creating value.
The number of shares outstanding for EGRX has been increased compared to 1 year ago.
The number of shares outstanding for EGRX has been reduced compared to 5 years ago.
The debt/assets ratio for EGRX is higher compared to a year ago.
2.2 Solvency
EGRX has an Altman-Z score of 1.92. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
EGRX's Altman-Z score of 1.92 is fine compared to the rest of the industry. EGRX outperforms 70.14% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that EGRX is not too dependend on debt financing.
The Debt to Equity ratio of EGRX (0.25) is worse than 69.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.92 |
ROIC/WACC1.6
WACC6.59%
2.3 Liquidity
EGRX has a Current Ratio of 2.16. This indicates that EGRX is financially healthy and has no problem in meeting its short term obligations.
EGRX has a Current ratio of 2.16. This is in the lower half of the industry: EGRX underperforms 75.77% of its industry peers.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.67, EGRX is doing worse than 78.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
Measured over the past years, EGRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.81% on average per year.
EGRX shows a decrease in Revenue. In the last year, the revenue decreased by -5.40%.
EGRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.99% yearly.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS growth Q2Q-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Revenue growth Q2Q-12.82%
3.2 Future
EGRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.47% yearly.
Based on estimates for the next years, EGRX will show a small growth in Revenue. The Revenue will grow by 0.24% on average per year.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 0.94 indicates a rather cheap valuation of EGRX.
Compared to the rest of the industry, the Price/Earnings ratio of EGRX indicates a rather cheap valuation: EGRX is cheaper than 99.49% of the companies listed in the same industry.
EGRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
A Price/Forward Earnings ratio of 1.32 indicates a rather cheap valuation of EGRX.
Based on the Price/Forward Earnings ratio, EGRX is valued cheaply inside the industry as 99.83% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.72, EGRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.94 | ||
| Fwd PE | 1.32 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EGRX is valued cheaply inside the industry as 98.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.73 |
4.3 Compensation for Growth
The decent profitability rating of EGRX may justify a higher PE ratio.
EGRX's earnings are expected to decrease with -26.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.06
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
5. Dividend
5.1 Amount
EGRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EAGLE PHARMACEUTICALS INC
NASDAQ:EGRX (5/2/2024, 7:00:01 PM)
After market: 4.4 0 (0%)4.4
+0.21 (+5.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap57.16M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.94 | ||
| Fwd PE | 1.32 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y
EPS growth Q2Q
EPS Next Y-40.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y